Principal Financial Group
MGX icon

Principal Financial Group’s Metagenomi Therapeutics MGX Stock Holding History

Principal Financial Group’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-350,859
Closed -$3.7M – 2478
2024
Q1 		$3.7M Buy
+350,859
New +$4.03M ﹤0.01% 1660

Other funds holding MGX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group's MGX Position: Q2 2024 in Review

Principal Financial Group sold out of Metagenomi Therapeutics (MGX) in Q2 2024, closing a stake of 350,859 shares — an estimated $3.7M sold.

Principal Financial Group first reported a position in MGX in Q1 2024 and held it in 1 quarter. The position peaked at $3.7M in Q1 2024. 54 funds tracked by Wall St. Rank hold MGX as of Q2 2024.

  • Principal Financial Group reported no remaining Metagenomi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 350,859 Metagenomi Therapeutics shares in Q2 2024, an estimated $3.7M.
  • Principal Financial Group first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 1 quarter.
  • Principal Financial Group's Metagenomi Therapeutics position peaked at $3.7M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.